Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ReCol 17 is a recombinant humanized Type XVII collagen (COL17A1) developed by Chuangjian Medical (Trautec). Type XVII collagen is a specialized transmembrane protein that plays a critical role in maintaining the niche of hair follicle stem cells (HFSCs) and melanocyte stem cells within the hair follicle bulge. The depletion of COL17A1, often associated with aging or DNA damage, leads to the miniaturization of hair follicles, resulting in hair thinning and premature graying. ReCol 17 is designed as a topical cosmetic ingredient for scalp application, aiming to restore the structural integrity of the hair follicle environment, promote scalp health, and stimulate hair growth. It is produced using high-density fermentation and purification processes to ensure high purity and biocompatibility for cosmetic and personal care applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ReCol 17.